National Cancer Institute; Notice of Meeting, 76837 [2023-24584]
Download as PDF
<![CDATA[
Federal Register / Vol. 88, No. 214 / Tuesday, November 7, 2023 / Notices
Contact Person: Paulette S. Gray, Ph.D.,
Director, Division of Extramural Activities,
National Cancer Institute—Shady Grove,
National Institutes of Health, 9609 Medical
Center Drive, 7th Floor, Room 7W444,
Bethesda, MD 20892, 240–276–6340, grayp@
mail.nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: NCAB:
https://deainfo.nci.nih.gov/advisory/ncab/
ncabmeetings.htm, where an agenda,
instructions for accessing the virtual NCAB
meetings, and any additional information for
the meetings will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 2, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2023–24578 Filed 11–6–23; 8:45 am]
BILLING CODE 4140–01–P
Place: National Cancer Institute Shady
Grove, 9609 Medical Center Drive, Rockville,
MD 20850 (Virtual Meeting).
Contact Person: Christopher D. Kane,
Ph.D., Health Science Administrator and
Program Officer, Office of Scientific
Operations, NCI at Frederick, National
Cancer Institute, National Institutes of
Health, 1050 Boyles Street, Building 427,
Room 4, Frederick, Maryland 21702,
christopher.kane@nih.gov.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: FNLAC:
https://deainfo.nci.nih.gov/advisory/fac/
fac.htm, where an agenda and any additional
information for the meeting will be posted
when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.392, Cancer Construction;
93.393, Cancer Cause and Prevention
Research; 93.394, Cancer Detection and
Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology
Research; 93.397, Cancer Centers Support;
93.398, Cancer Research Manpower; 93.399,
Cancer Control, National Institutes of Health,
HHS)
Dated: November 2, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory
Committee Policy.
khammond on DSKJM1Z7X2PROD with NOTICES
[FR Doc. 2023–24584 Filed 11–6–23; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Cancer Institute; Notice of
Meeting
National Institutes of Health
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of a
meeting of the Frederick National
Laboratory Advisory Committee to the
National Cancer Institute.
The meeting will be held virtually
and is open to the public. Individuals
who plan to view the virtual meeting
and need special assistance or other
reasonable accommodations to view the
meeting, should notify the Contact
Person listed below in advance of the
meeting. The meeting will be videocast
and can be accessed from the NIH
Videocasting and Podcasting website
(https://videocast.nih.gov).
Name of Committee: Frederick National
Laboratory Advisory Committee to the
National Cancer Institute.
Date: February 29, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: Ongoing and new activities at the
Frederick National Laboratory for Cancer
Research.
VerDate Sep<11>2014
16:30 Nov 06, 2023
Jkt 262001
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Peter Tung at 240–669–5483 or
peter.tung@nih.gov. Licensing
information and copies of the patent
applications listed below may be
obtained by communicating with the
Technology Transfer and Intellectual
SUMMARY:
PO 00000
Frm 00119
Fmt 4703
Sfmt 4703
76837
Property Office, National Institute of
Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD, 20852; tel.
301–496–2644. A signed Confidential
Disclosure Agreement will be required
to receive copies of unpublished patent
applications related to the invention.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Beta Globin Mimetic Peptides and
Their Use
Description of Technology: Feedback
vasodilation by endothelium-derived
nitric oxide (NO) is under the regulation
of globins. Inventors discovered that not
only the alpha globin but also the beta
globin subunits of hemoglobin are
expressed in the human artery wall,
with beta globin interacting directly
with endothelium-derived nitric oxide
synthase (eNOS). This discovery of
tetrameric hemoglobin binding to eNOS
has led inventors to develop novel
mimetic peptides that disrupt the
binding of beta globin to eNOS,
diminishing the ability of hemoglobin to
restrict NO release and thereby
enhancing NO-mediated feedback
vasodilation. These agents can be used
to increase NO signaling from
endothelial cells and thus inhibit,
prevent, or reverse vasoconstriction.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404, as well as for further
development and evaluation under a
research collaboration.
Potential Commercial Applications:
• Novel peptides to treat vascular
diseases characterized by
vasoconstriction, excess alpha
adrenergic signaling, or insufficient
nitric oxide signaling. Applications
could range from cerebral vasospasm to
pulmonary hypertension, to chronic
kidney disease, to transfusion medicine,
to erectile dysfunction, and to exercise
physiology.
Competitive Advantages:
• New pathway for regulation of
vasoconstriction/vasodilation that is
separate from the pathways that current
products available for treating nitric
oxide deficiency target. Combination
therapy with current vasoconstriction/
vasodilation medications of different
mechanisms may be possible.
• Enhancement of NO release at the
junction between the endothelial cell
and smooth muscle cell may provide
greater potency and fewer off-target
effects than other forms of NO delivery.
Development Stage:
• Peptides have been tested in human
and canine arteries ex vivo.
E:\FR\FM\07NON1.SGM
07NON1
]]>Agencies
[Federal Register Volume 88, Number 214 (Tuesday, November 7, 2023)]
[Notices]
[Page 76837]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-24584]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of Meeting
Pursuant to section 1009 of the Federal Advisory Committee Act, as
amended, notice is hereby given of a meeting of the Frederick National
Laboratory Advisory Committee to the National Cancer Institute.
The meeting will be held virtually and is open to the public.
Individuals who plan to view the virtual meeting and need special
assistance or other reasonable accommodations to view the meeting,
should notify the Contact Person listed below in advance of the
meeting. The meeting will be videocast and can be accessed from the NIH
Videocasting and Podcasting website (https://videocast.nih.gov).
Name of Committee: Frederick National Laboratory Advisory
Committee to the National Cancer Institute.
Date: February 29, 2024.
Time: 1:00 p.m. to 4:00 p.m.
Agenda: Ongoing and new activities at the Frederick National
Laboratory for Cancer Research.
Place: National Cancer Institute Shady Grove, 9609 Medical
Center Drive, Rockville, MD 20850 (Virtual Meeting).
Contact Person: Christopher D. Kane, Ph.D., Health Science
Administrator and Program Officer, Office of Scientific Operations,
NCI at Frederick, National Cancer Institute, National Institutes of
Health, 1050 Boyles Street, Building 427, Room 4, Frederick,
Maryland 21702, [email protected].
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Information is also available on the Institute's/Center's home
page: FNLAC: https://deainfo.nci.nih.gov/advisory/fac/fac.htm, where
an agenda and any additional information for the meeting will be
posted when available.
(Catalogue of Federal Domestic Assistance Program Nos. 93.392,
Cancer Construction; 93.393, Cancer Cause and Prevention Research;
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer
Control, National Institutes of Health, HHS)
Dated: November 2, 2023.
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2023-24584 Filed 11-6-23; 8:45 am]
BILLING CODE 4140-01-P
